Formulytica leadership change

Formulytica is pleased to announce the appointment of Dr Michael Andrews Luke as Chief Executive Officer (CEO) and Managing Director, effective 23 July 2025, as part of a planned leadership transition.

Michael has over 20 years of experience in drug development and R&D leadership across biotech, pharmaceuticals, and cosmetics, and has been a key member of Formulytica’s executive team for the past 7 years.

Michael succeeds Dr Richard Buchta, who has stepped down as CEO and Managing Director after 10 years of outstanding leadership. Richard remains with the company as a Non-Executive Director and Advisor.

This transition ensures continuity in leadership and positions Formulytica for its next phase of innovation and growth.

For more information, read the full announcement.